|
Hiroyoshi Doihara
Department Kawasaki Medical School Kawasaki Medical School, Department of General Surgery, Position Professor with Special Assignment |
|
| Article types | 原著 |
| Language | English |
| Peer review | Peer reviewed |
| Title | Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. |
| Journal | Formal name：Clinical breast cancer Abbreviation：Clin Breast Cancer ISSN code：19380666/15268209 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 20(2),pp.117-124.e4 |
| Author and coauthor | Takahashi Yuko, Iwamoto Takayuki, Suzuki Yoko, Kajiwara Yukiko, Hatono Minami, Tsukioki Takahiro, Kawada Kengo, Kochi Mariko, Ikeda Hirokuni, Shien Tadahiko, Taira Naruto, Matsuoka Junji, Doihara Hiroyoshi, Toyooka Shinichi |
| Publication date | 2020/04 |
| Summary | INTRODUCTION:Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy.PATIENTS AND METHODS:We retrieved publicly available complementary DNA microarray data from 399 human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer samples from patients who underwent standard neoadjuvant chemotherapy. We analyzed the messenger RNA (mRNA) expression levels of key breast cancer markers and therapeutic target genes according to residual cancer burden (RCB) classification: RCB-0/I, RCB-II, and RCB-III.RESULTS:Among hormone receptor-positive samples, there were more luminal A tumors by PAM50 (Prediction Analysis of Microarray 50 [Prosigna], aka Prosigna Breast Cancer Prognostic Gene Signature Assay) in RCB-III than in RCB-0/I and RCB-II (P < .01). The mRNA expressions of ESR1 and PGR were significantly higher, and that of MKI67 was lower in RCB-II and RCB-III than in RCB-0/I. The mRNA expression of cyclin D1 was up-regulated in RCB-III and that of CDKN2A was down-regulated in RCB-III (P = .027 and < .01). Among triple-negative (TN) samples, RCB-III had higher clinical stage and more lymph node-positive samples than RCB-0/1 and RCB-II (P < .01). In both subtypes, VEGF-C expression was significantly higher in RCB-III than in RCB-0/I and RCB-II.CONCLUSION:In hormone receptor-positive breast cancer, biological features such as luminal A were associated with RCB; this trend was not observed in TN breast cancer. Further, some targeted therapies should be tested as new strategies after standard neoadjuvant chemotherapy in future clinical trials. |
| DOI | 10.1016/j.clbc.2019.07.001 |
| PMID | 31570267 |